Idorsia has a strong and visionary leadership team, with the power and drive to create more remarkable innovations and more medicines. Our people show up every day with energy, intellect and creativity.
The Idorsia Executive Committee
Date of birth: 3 April 1955
Nationality: Swiss and French
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997. Co-founded Actelion in 1997, taking the reigns as CEO from 1999 until the acquisition by Johnson & Johnson for $30 billion in 2017. Joined Idorsia as CEO when the company was established in June 2017.
Date of birth: 27 December 1955
Nationality: Swiss and French
Education: MD, specialization in pediatrics and in neonatal intensive care, educated at the University of Nancy, France; further training in physiology and pharmacology at McGill University, Montreal, Canada, and at the University of California, San Francisco, US.
Professional background: Assistant professor, neonatology. Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche. Co-founded Actelion in 1997, Head of Drug Discovery, Pharmacology & Preclinical Development, Actelion, 1997–2009. Chief Scientific Officer of Actelion, 2009–2017. Joined Idorsia as Chief Scientific Officer when the company was established in June 2017.
Officer of the Legion of Honour
Date of birth: 19 November 1956
Education: MD, pulmonology and PhD in life science, Paris University, France.
Professional background: Merck Serono, Chief Medical Officer; Serono, Chief Medical Officer International; various executive positions at Astra, Fisons, Rhône-Poulenc Rorer, Glaxo Wellcome, GSK and Chiron. Head of Global Clinical Development for Actelion, 2009–2017. Joined Idorsia as Head of Global Clinical Development when the company was established in June 2017.
Date of birth: 23 June 1965
Education: BSc Medical Biochemistry with Honors at the University of Birmingham, UK.
Professional background: From 1995–2012, various marketing and General Manager positions at GlaxoSmithKline in the UK, USA, and Denmark; Global President of Stiefel, a GSK company, 2012–2014; SVP, Head Global Franchises & Platforms (Pharmaceuticals), GSK, 2014–2018.
Date of birth: 30 October 1963
Education: Master’s degree in Business Administration from EMLYON Business School, Lyon, France.
Professional background: From 1994–2011 held various financial positions at Pierre Fabre SA, an international pharmaceutical and dermo-cosmetic company, serving as CFO from 2002. CFO of Actelion, 2013–2017. Joined Idorsia as CFO when the company was established in June 2017.
The Idorsia Leadership Team
Date of birth: 7 September 1968
Education: Master’s degree in Business Administration, Monetary Economics and Corporate Law from the University of Zurich and Chartered Financial Analyst (CFA).
Professional background: Built a deep expertise and network in the area capital markets, while focusing on gaining an understanding for the pharmaceutical and biotechnology market. Stepping stones as sell-side analyst, buy-side analyst and fund manager include: Equity analyst for European Pharmaceuticals at Warburg Dillon Read (1997–1999) and analyst/ fund manager at Julius Baer (2000–2005). Senior financial analyst covering Swiss/European pharmaceutical/biotechnology stocks for Bank Leu (2005), Bank Sarasin (2006) and Bank Vontobel (2007). Team leader for Life Sciences Equity Research at Bank Vontobel (2008–2014). Head of Investor Relations & Corporate Communications for Actelion 2014-2017. Joined Idorsia as Head of Investor Relations & Corporate Communications when the company was established in June 2017.
Date of birth: 11 September 1978
Nationality: Swiss and Russian
Education: Master degree in Human Resources Management in Russia, Bachelor degree in Finance in Russia; further education and training in Business Administration and Communication in the US (California State University East Bay, Hayward) and in Coaching and Neuro-linguistic Programming in Erickson College, Vancouver, Canada.
Professional background: HR Manager and Organizational Development Manager at British American Tobacco in Russia and in Switzerland 2003-2007; HR Director for Global Clinical Development and Head of Global Talent Acquisition and Development at Actelion 2007-2017. As of 2013 practicing independent professional coach. Joined Idorsia as Head of Human Resources when the company was established in June 2017.
Date of birth: 20 February 1970
Education: J.D. from the University of Bern, Switzerland. Admission to the Bar of the Canton of Bern.
Professional Background: Legal Counsel for transactions and litigation 2000-2007 in a telecommunications company, 2007-2017 Associate General Counsel and Deputy Group Compliance Officer at Actelion. Joined Idorsia as Group General Counsel when the company was established in June 2017.
Date of birth: 16 December 1966
Education: Ph.D. in applied Physico-Chemistry (polymer sciences) in France.
Professional background: 1998–2005. Principal Scientist and Technology Matrix Leader for Parenteral Sustained Delivery systems in the Pharmaceutical Department of Novartis Pharma AG, 2005-2013 CMC project leader at Actelion Pharmaceuticals Ltd, 2013 - 2017 Head Quality Assurance (GMP/GDP) at Actelion Pharmaceuticals Ltd. Joined Idorsia as Head of Pharmaceutical Development when the company was established in June 2017.
Date of birth: 14 January 1962
Education: Doctoral degree. Dr. Phil.II at the University of Basel, Switzerland, further education at Stanford University, School of Medicine, Stanford, CA, US.
Professional background: Research Scientist, Thrombosis Group at Hoffmann-La Roche, 1994-1997. Project Leader “Novel Oral Anticoagulant Project” at Hoffmann-La Roche, 1997-2002. Head of Biology, Axovan Pharmaceutical, 2002-2003. Senior Group Leader, Immunology/Thrombosis Biology at Actelion Pharmaceuticals Ltd, 2003-2016. Head DD Biology, at Actelion Pharmaceuticals Ltd, 2016-2017. Joined Idorsia as Head of Drug Discovery Biology when the company was established in June 2017.
Date of birth: 1 April 1967
Education: PhD in Biochemistry/Life Sciences, Universities of Kaiserslautern and Frankfurt, Msc Toxicology, University of Surrey, UK
Professional background: From 1993 until 2004, various positions in project toxicology/drug development at Sandoz, Ciba and F. Hoffmann-La Roche, 2004-2017 Head of Toxicology, Actelion, since 2011 Head of Preclinical Development, Actelion. Joined Idorsia as Head of Drug Discovery Pharmacology & Preclinical Development when the company was established in June 2017.
Date of birth: 9 February 1968
Education: PhD, synthetic organic chemistry at the University of Bern, Switzerland followed by post-doctoral training at The Scripps Research Institute (TSRI) in LaJolla, California, USA.
Professional background: From 1999 until 2012, various positions of increasing responsibility in Actelion's drug discovery chemistry department contributing to the identification of several lead compounds including macitentan for PAH and daridorexant for insomnia. Senior Group Leader Chemistry Technologies 2012-2017. Joined Idorsia when the company was established in June 2017 as a Senior Group Leader in Drug Discovery Chemistry. Head of Drug Discovery Chemistry at Idorsia since July 2019.
Date of birth: 21 January 1970
Nationality: Swiss and German
Education: PhD, organic chemistry at the ETH Zurich, Switzerland.
Professional background: Various positions (Project Chemist, Group Leader, Head GMP production) in R&D and GMP manufacturing at Carbogen-Amcis 1999-2006. Set up fully integrated Chemistry Process R&D at Actelion in 2006. Joined Idorsia when the company was established in June 2017 as Head of Chemical Development, responsible for drug substance development and manufacturing from preclinical phase to launch and commercial supply. Head of Chemical Development and Commercial Manufacturing at Idorsia since July 2019.